NASDAQ: RSLS
Reshape Lifesciences Inc Stock

$0.31-0.05 (-13.89%)
Updated Apr 17, 2025
ReShape Lifesciences shares are trading... find out Why RSLS Price Moved with a free WallStreetZen account
Why Price Moved
RSLS Price
$0.31
Fair Value Price
N/A
Market Cap
$3.50M
52 Week Low
$0.30
52 Week High
$29.00
P/E
-0.02x
P/B
-13.82x
P/S
0.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.01M
Earnings
-$7.13M
Gross Margin
63.2%
Operating Margin
-88.57%
Profit Margin
-89.1%
Debt to Equity
-19.95
Operating Cash Flow
-$4M
Beta
0.9
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

RSLS Overview

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine RSLS's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
RSLS
Ranked
Unranked of 102

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$7.82A
$22.79A
$13.33A
View Top Medical Device Stocks

Be the first to know about important RSLS news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RSLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RSLS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RSLS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RSLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RSLS due diligence checks available for Premium users.

Valuation

RSLS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.02x
Industry
41.14x
Market
27.98x

RSLS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-13.82x
Industry
3.8x

RSLS's financial health

Profit margin

Revenue
$1.8M
Net Income
-$1.8M
Profit Margin
-97.6%
RSLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RSLS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$4.8M
Liabilities
$5.0M
Debt to equity
-19.95
RSLS's short-term liabilities ($4.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RSLS's short-term assets ($4.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RSLS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RSLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$687.0k
Investing
$0.0
Financing
$653.0k
RSLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RSLS vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
RSLS$3.50M-14.60%-0.02x-13.82x
HSCS$3.57M+7.84%-0.44x2.00x
XYLO$3.57M-4.81%-0.21x0.23x
VTAK$2.97M-4.48%-0.05x0.25x
NUWE$4.09M+4.71%-0.11x0.63x

Reshape Lifesciences Stock FAQ

What is Reshape Lifesciences's quote symbol?

(NASDAQ: RSLS) Reshape Lifesciences trades on the NASDAQ under the ticker symbol RSLS. Reshape Lifesciences stock quotes can also be displayed as NASDAQ: RSLS.

If you're new to stock investing, here's how to buy Reshape Lifesciences stock.

What is the 52 week high and low for Reshape Lifesciences (NASDAQ: RSLS)?

(NASDAQ: RSLS) Reshape Lifesciences's 52-week high was $29.00, and its 52-week low was $0.30. It is currently -98.93% from its 52-week high and 3.33% from its 52-week low.

How much is Reshape Lifesciences stock worth today?

(NASDAQ: RSLS) Reshape Lifesciences currently has 11,276,248 outstanding shares. With Reshape Lifesciences stock trading at $0.31 per share, the total value of Reshape Lifesciences stock (market capitalization) is $3.50M.

Reshape Lifesciences stock was originally listed at a price of $1,305,001.31 in Oct 6, 2016. If you had invested in Reshape Lifesciences stock at $1,305,001.31, your return over the last 8 years would have been -100%, for an annualized return of -85.14% (not including any dividends or dividend reinvestments).

How much is Reshape Lifesciences's stock price per share?

(NASDAQ: RSLS) Reshape Lifesciences stock price per share is $0.31 today (as of Apr 17, 2025).

What is Reshape Lifesciences's Market Cap?

(NASDAQ: RSLS) Reshape Lifesciences's market cap is $3.50M, as of Apr 21, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Reshape Lifesciences's market cap is calculated by multiplying RSLS's current stock price of $0.31 by RSLS's total outstanding shares of 11,276,248.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.